(Q37570873)

21 August 2017

1 reference

title

History of the use of HPV testing in cervical screening and in the management of abnormal cervical screening results (English)

1 reference

21 August 2017

J Thomas Cox

1

1 reference

PubMed ID

19651367

21 August 2017

language of work or name

1 reference

1 July 2009

1 reference

Journal of Clinical Virology

21 August 2017

1 reference

21 August 2017

45 Suppl 1

1 reference

21 August 2017

S3-S12

1 reference

A papillomavirus DNA from a cervical carcinoma and its prevalence in cancer biopsy samples from different geographic regions

21 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2809%2970002-2

7 January 2021

A new type of papillomavirus DNA, its presence in genital cancer biopsies and in cell lines derived from cervical cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2809%2970002-2

7 January 2021

Structure and transcription of human papillomavirus sequences in cervical carcinoma cells

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2809%2970002-2

7 January 2021

Definition of linear antigenic regions of the HPV16 L1 capsid protein using synthetic virion-like particles

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2809%2970002-2

7 January 2021

Should cervical cytologic testing be augmented by cervicography or human papillomavirus deoxyribonucleic acid detection?

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2809%2970002-2

7 January 2021

Clinical role of HPV testing

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2809%2970002-2

7 January 2021

Where's the high-grade cervical neoplasia? The importance of minimally abnormal Papanicolaou diagnoses

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2809%2970002-2

7 January 2021

Evaluating the role of HPV testing for women with equivocal Papanicolaou test findings

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2809%2970002-2

7 January 2021

Comparison of management algorithms for the evaluation of women with low-grade cytologic abnormalities

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2809%2970002-2

7 January 2021

Human papillomavirus testing by hybrid capture appears to be useful in triaging women with a cytologic diagnosis of atypical squamous cells of undetermined significance

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2809%2970002-2

7 January 2021

Reflex human papillomavirus deoxyribonucleic acid testing in women with abnormal Papanicolaou smears

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2809%2970002-2

7 January 2021

ASCUS-LSIL Triage Study. Design, methods and characteristics of trial participants

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2809%2970002-2

7 January 2021

Comparison of three management strategies for patients with atypical squamous cells of undetermined significance: baseline results from a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2809%2970002-2

7 January 2021

2001 Consensus Guidelines for the management of women with cervical cytological abnormalities

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2809%2970002-2

7 January 2021

Identifying women with cervical neoplasia: using human papillomavirus DNA testing for equivocal Papanicolaou results

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2809%2970002-2

7 January 2021

2006 consensus guidelines for the management of women with abnormal cervical screening tests

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2809%2970002-2

7 January 2021

2006 consensus guidelines for the management of women with abnormal cervical cancer screening tests

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2809%2970002-2

7 January 2021

Virologic versus cytologic triage of women with equivocal Pap smears: a meta-analysis of the accuracy to detect high-grade intraepithelial neoplasia

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2809%2970002-2

7 January 2021

Cost-effectiveness of alternative triage strategies for atypical squamous cells of undetermined significance

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2809%2970002-2

7 January 2021

Prospective follow-up suggests similar risk of subsequent cervical intraepithelial neoplasia grade 2 or 3 among women with cervical intraepithelial neoplasia grade 1 or negative colposcopy and directed biopsy

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2809%2970002-2

7 January 2021

Postcolposcopy management strategies for women referred with low-grade squamous intraepithelial lesions or human papillomavirus DNA-positive atypical squamous cells of undetermined significance: a two-year prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2809%2970002-2

7 January 2021

Human papillomavirus testing and the outcome of treatment for cervical intraepithelial neoplasia

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2809%2970002-2

7 January 2021

Addition of high-risk HPV testing improves the current guidelines on follow-up after treatment for cervical intraepithelial neoplasia

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2809%2970002-2

7 January 2021

Clinical utility of HPV-DNA detection: triage of minor cervical lesions, follow-up of women treated for high-grade CIN: an update of pooled evidence

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2809%2970002-2

7 January 2021

Human papillomavirus testing following loop electrosurgical excision procedure identifies women at risk for posttreatment cervical intraepithelial neoplasia grade 2 or 3 disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2809%2970002-2

7 January 2021

Baseline cytology, human papillomavirus testing, and risk for cervical neoplasia: a 10-year cohort analysis.

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2809%2970002-2

7 January 2021

Human papillomavirus testing in primary cervical screening.

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2809%2970002-2

7 January 2021

HPV testing in primary screening of older women

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2809%2970002-2

7 January 2021

Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2809%2970002-2

7 January 2021

Long-term follow-up of cervical abnormalities among women screened by HPV testing and cytology-Results from the Hammersmith study.

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2809%2970002-2

7 January 2021

Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2809%2970002-2

7 January 2021

Efficacy of HPV DNA testing with cytology triage and/or repeat HPV DNA testing in primary cervical cancer screening

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2809%2970002-2

7 January 2021

The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice.

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2809%2970002-2

7 January 2021

Human papillomavirus type 16 infections and 2-year absolute risk of cervical precancer in women with equivocal or mild cytologic abnormalities

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2809%2970002-2

7 January 2021

Comparison of the Third Wave Invader human papillomavirus (HPV) assay and the digene HPV hybrid capture 2 assay for detection of high-risk HPV DNA

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2809%2970002-2

7 January 2021

Invader human papillomavirus (HPV) type 16 and 18 assays as adjuncts to HPV screening of cervical papanicolaou smears with atypical squamous cells of undetermined significance.

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2809%2970002-2

7 January 2021

Human papillomavirus mRNA and p16 detection as biomarkers for the improved diagnosis of cervical neoplasia

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2809%2970002-2

7 January 2021

A cross-sectional study of a prototype carcinogenic human papillomavirus E6/E7 messenger RNA assay for detection of cervical precancer and cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2809%2970002-2

7 January 2021

Isolation of RNA from residual BD SurePath liquid-based cytology specimens and detection of HPV E6/E7 mRNA using the PreTectt HPV-Proofer assay

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2809%2970002-2

7 January 2021

Clinical performance of the APTIMA HPV Assay for the detection of high-risk HPV and high-grade cervical lesions

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2809%2970002-2

7 January 2021

Assessment of new technologies for cervical cancer screening.

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2809%2970002-2

7 January 2021

Immunostaining for p16INK4a used as a conjunctive tool improves interobserver agreement of the histologic diagnosis of cervical intraepithelial neoplasia.

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2809%2970002-2

7 January 2021

Use of p16-INK4A overexpression to increase the specificity of human papillomavirus testing: a nested substudy of the NTCC randomised controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2809%2970002-2

7 January 2021

Human papillomavirus infection and cervical cytology in women screened for cervical cancer in the United States, 2003-2005.

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2809%2970002-2

7 January 2021

Five-year experience of human papillomavirus DNA and Papanicolaou test cotesting

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2809%2970002-2

7 January 2021

Cost-effectiveness of cervical cancer screening with human papillomavirus DNA testing and HPV-16,18 vaccination

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2809%2970002-2

7 January 2021

Cervical Cancer Screening: From the Papanicolaou Smear to the Vaccine Era

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2809%2970002-2

7 January 2021

10.1016/S1386-6532(09)70002-2

Identifiers

DOI

1 reference

21 August 2017

1 reference

PubMed ID

19651367